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Abstract
Tumors appear as heterogeneous tissues that consist of tumor cells surrounding by a 
tumor microenvironment (TME). TME is a complex network composed of extracellu-
lar matrix (ECM), stromal cells, and immune/inflammatory cells that drive cancer cells 
fate from invasion to intravasation and metastasis. The stromal-inflammatory interface 
represents a dynamic space, in which exchange of numerous molecular information is 
associated with the transition into tumorigenic microenvironment. Recruitment, activa-
tion, and reprogramming of stromal and immune/inflammatory cells in the extracellular 
space are the consequences of a reciprocal interaction between TME and cancer cells. 
Recent data suggest that cancer development is influenced by TME and controlled by 
the host’s immune system, underlying the importance of TME components and immune 
biomarkers in the determination of prognosis and response to therapy. The immune clas-
sification has prognostic value and may be a useful supplement to the histopathological, 
molecular, and TNM classifications. Nevertheless, the complexity of quantitative immu-
nohistochemistry and the variable assay protocols, stromal and immune cell types ana-
lyzed underscore the need to harmonize the quantified methods. It is therefore important 
to incorporate TME and immune scoring in determinations of cancer prognosis and to 
make sure they become a routine part of the histopathological diagnostic and prognostic 
assessment of patients.
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1. Introduction
Cancer is usually viewed as a complex process of multiple disorders that are mostly driven by 
somatic mutation with the involvement of several hallmarks: genomic instability, sustaining 
proliferative signaling, resisting cell death, enabling replicative immortality, inflammation, 
evading the immune system, de novo angiogenesis, invasion, and metastasis. The outcome 
prediction in cancer is usually achieved by histopathological analysis of tissue samples 
obtained by biopsies or surgical specimens from primary tumor or metastatic localization. 
However, the heterogeneity in the histological appearance of different tumors (intertumor 
heterogeneity) as well as of different areas in the same tumor (intratumor heterogeneity) is of 
uncontested relevant and can explain the histopathological classification of tumors based on 
the morphological patterns. In the last decade, the advent of molecular pathology has allowed 
the definition of molecular subtyping for several cancers, which does not completely overlap 
with prevailing histopathological classifications [1].
In current practice, TNM classification appears as a sample method of tumor staging used 
worldwide, and based on tumor burden (T), lymph nodes status (N), and presence of metas-
tases (M). However, the TNM classification provides limited prognostic information in cancer 
and does not predict response to therapy. Moreover, cancer outcome can differ significantly 
between patients whose cancers are at the same TNM stage.
Tumor appears as heterogeneous tissues that consist of tumor cells surrounded by a tumor 
microenvironment (TME). TME is a complex network composed of extracellular matrix (ECM), 
stromal cells (fibroblasts, adipocytes, neural and neuroendocrine (NE) cells, endothelial cells 
(ECs), and pericytes), immune and inflammatory cells that drive cancer cells fate from inva-
sion to intravasation and metastasis. Cancer cells need cellular, biochemical, and biophysi-
cal stimuli originating from a more adapted microenvironment by recruiting and educating 
various types of normal cells into their neighborhood. The stromal-inflammatory interface 
represents a dynamic space characterized by reversible stromal and epithelial events. Within 
this dynamic space, exchange of numerous molecular information is associated with the 
transition into tumorigenic microenvironment and includes growth factors (GFs), cytokines, 
chemokines, enzymes, matrix proteins, and metabolic intermediates. Recruitment, activation, 
reprogramming, and persistence of stromal and immune/inflammatory cells in the extracellu-
lar space are the consequences of a reciprocal interaction between TME and cancer cells [2, 3].
Recent data suggest that cancer development is influenced by TME and controlled by the 
host’s immune system, underlying the importance of including TME components and immu-
nological biomarkers in the determination of prognosis and response to therapy, a concept 
that has been termed as microenvironment score and immunoscore. Increasingly, data col-
lected from cancer tissue samples demonstrate that immune classification has prognostic 
value and may be a useful supplement to the histopathological, molecular, and TNM clas-
sifications. Nevertheless, the complexity of quantitative immunohistochemistry and the vari-
able assay protocols, stromal and immune cell types analyzed and tumor-sampling criteria 
underscore the need to harmonize the quantified methods. It is therefore important to incor-
porate TME and immune scoring in determinations of cancer prognosis and to make sure 
they become a routine part of the histopathological diagnostic and prognostic assessment of 
patients with cancer.
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2. Tumor microenvironment components
2.1. Non-immune/inflammatory stromal cells
Non-immune/inflammatory stromal cells comprise fibroblasts, adipocytes, neural and neuro-
endocrine cells, endothelial cells, pericytes, and mesenchymal stem cells (MSCs) (Figure 1 and 
Table 1).
2.1.1. Cancer-associated fibroblasts
Cancer-associated fibroblasts (CAFs) are a sub-population of activated fibroblasts with myo-
fibroblastic phenotype that represent the predominant non-inflammatory stromal cell type 
in the TME. CAFs are heterogeneous cells of multiple origins, which are usually identified 
according to their different origins by expression of proteins such as mesenchymal biomark-
ers (vimentin and fibronectin), fibroblast-secreted protein-1 (FSP-1), α-smooth muscle actin 
(αSMA), tenascin-C, platelet-derived growth factor receptor (PDGFR), and fibroblast activa-
tion protein (FAP) [4, 5]. CAFs accumulation in the TME is often correlated with poor prog-
nosis. They may promote tumor development and progression by promoting angiogenesis or 
by interacting with immune-inflammatory cells and neuroendocrine cells through different 
cell factors and cytokines [2]. CAFs may also hinder antitumor immune responses [4]. Indeed, 
cancer cells produce TGF-β that activates adjacent CAFs. In turn, CAFs promote tumor pro-
gression by releasing numerous interleukins (IL-1, IL-6, IL-8, and IL-22) and chemokines 
(CXC-chemokine ligand CXCL and CC-chemokine ligand CCL) [2]. CAFs can also secrete 
various chemotactic GFs (EGF, FGF, HGF PDGF, and VEGF), ECM proteins (collagens, fibro-
nectins, tenascin C, and SPARC), enzymes such as matrix metalloproteinases (MMPs), lysyl 
oxidases (LOX) family, and cyclooxygenase 2 (COX2) [6].
Figure 1. Tumor microenvironment is a complex network composed of extracellular matrix (ECM), stromal cells 
(fibroblasts, endothelial cells and pericytes) and immune and inflammatory cells (T cells, B cells, natural killer ‘NK’ cells, 
dendritic cells, macrophages and myeloid-derived suppressor cells). The stromal-inflammatory interface represents 
a dynamic space contains growth factors, cytokines and chemokines. Recruitment, activation, reprogramming and 
persistence of stromal and immune/inflammatory cells in the extracellular space are the consequences of reciprocal 
interactions between tumor microenvironment components and tumor cells.
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Non-immune/
inflammatory 
stromal cell
Main markers Main functions Potential therapeutic targets
Cancer-associated 
fibroblasts (CAFs)
Vimentin, 
fibronectin, FSP-1, 
αSMA, tenascin-C, 
PDGFR Endosialin 
(CD248), and FAP
• Tumor progression (IL-1, IL-6, 
IL-8, IL-22, CXCL1 to CXCL12/
SDF1, CCL2 and CCL20, VEGF, 
PDGF, EGF, FGF, HGF, fibronec-
tin, collagen I and III, EDA-
fibronectin, tenascin C, SPARC, 
MMPs, LOX family, and COX2
• Promote angiogenesis
• Hinder antitumor immune 
responses
Anti-CXCR-4 antibodies 
(CXCL12/SDF-1inhibition); 
anti-VEGF and anti-PDGF 
antibodies; MMP inhibitors; 
anti-IL6 antibodies; anti-HGF 
therapies; anti-FAP antibodies; 
Anti-TGFβ inhibitors; anti-IL-11 
and anti-THSB1 therapies
Cancer-associated 
adipocytes (CAAs)
FSP-1 expression • Produce adipokines (leptin, adi-
ponectin, and apelin), angiogenic 
factors (VEGF), TNF-α, IL-1β, 
IL-6, IL-8, MCP1, CCL2 and 
CCL5 and HGF
Antibodies anti-IL-6, anti-IL-8; 
anti-CCL2, COX2 and 
adiponectin inhibitors
Mesenchymal stem 
cells (MSCs)
Vimentin, CD29 
(β1integrin), CD44, 
CD73, CD90, CD105 
and STRO-1
• Stimulate tumor angiogenesis 
through VEGF expression
• Multilineage potentiate
• Immunoregulatory function
Nano-engineered MSCs are used 
as targeted therapeutic carriers
Endothelial cells Tip cells: VEGFR1low, 
VEGFR2high, Dll4high, 
and CD34+
Stalk cells: 
VEGFR1high, 
VEGFR2low, Dll4low 
CD34−.
• Implicated in metastatic niche 
and dormancy through TGF-β1 
and POSTN
avβ1, avβ2, a5β1 integrin 
inhibitors; anti-VEGF and 
VEGFR agents
Pericytes αSMA, Desmin, 
NG2 (CSPG4), 3G5 
antigen, PDGFR-β 
and Endosialin 
(CD248)
• Modulate the magnitude of 
immune responses
• Prevent lymphocyte extravasa-
tion and activation in tumor 
tissue
Anti-ANG2 antibody
VEGFR and PDGFR-β 
antagonists; VEGFR, PDGFR-β, 
and Tie-2 agonists; anti-RSG5 
and anti-PD/PD-L1 therapies
Neural cells PGP9.5. and NGF • Favors tumor progression
• Norepinephrine, impact T-cells 
by inhibiting the generation 
of CTLs through inhibition of 
TNF-α synthesis
Anti-NGF blocking antibodies, 
NT3 and NT4 targeted therapies; 
GDNF inhibitors; anti-NGF 
antibodies; anti-PTN antibodies 
and N-syndecan inhibitors; 
BDNF inhibitors
Abbreviations: ANG2: angiopoietin-2; Integrins αv: avβ1, avβ2; BDNF: brain-derived neurotrophic factor; CCL: 
chemokine ligand; COX: cyclooxygenase; CSF: colony stimulating factor; CXCL: C-X-C chemokine ligand; CXCR: C-X-C 
chemokine receptor; CSPG4: Chondroitin sulfate proteoglycan 4; FAP: fibroblast activation protein; FRb: folate receptor 
beta; GDNF: glial cell line-derived neurotrophic factor; HRG: histadine-rich glycoprotein; IL: interleukin; MMP: matrix 
metalloproteinase; NGF: nerve growth factor; NT: neurotrophin; PDGF: platelet-derived growth factor; PDGFR: platelet-
derived growth receptor; PD1: programmed cell death protein; PD-L1: programmed cell death ligand; PTN: pleiotropin; 
RSG5: regulator of protein signaling 5; SDF: stromal-derived factor; TIMP: tissue inhibitor of metalloproteinase; TGF: 
transforming growth factor; TLR: toll-like receptor; VEGF: vascular endothelial growth factor; VEGFR: vascular 
endothelial growth factor and receptor.
Table 1. Stromal cell types in tumor microenvironment: main markers and functions with potential therapeutic targets.
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2.1.2. Cancer-associated adipocytes
Cancer-associated adipocytes (CAAs) possess important secretory properties that may 
enhance tumor aggressiveness. Compared to normal adipocytes, CAAs are characterized by 
the loss of adipocyte differentiation, a smaller size, and FSP-1 expression (with lack of αSMA 
expression). They produce adipokines (leptin, adiponectin, and apelin), angiogenic factors 
and GFs (VEGF and HGF), tumor necrosis factor-α (TNF-α), interleukins (IL-1β, IL-6, and 
IL-8), and chemokines (MCP1, CCL2, and CCL5) [7]. They also exhibit an increased secre-
tion of fibronectin, collagen I/VI, and MMP-11/Stromelysin-3 [2, 8]. The activation of Wnt/
β-catenin pathway in response to Wnt3a secreted by cancer cells is essential to adipocytes 
reprogramming. The reprogrammed CAAs located close to cancer cells can initiate protu-
moral heterotypic paracrine and endocrine interactions. Another type of CAAs is the adipose 
stem cells (ASCs). ASCs can influence the TME by worsening the tumorigenic behavior of 
c-Met-producing cancer cells, which in turn creates an inflammatory TME. ASCs can interact 
with TME through TGF-β1-signaling pathway or promote angiogenesis by migrating toward 
tumor-conditioned media through the PDGF-BB/PDGF-β-signaling pathway [5].
2.1.3. Angiogenic vascular cells
Blood vessels are composed of perivascular cells termed as pericytes, endothelial cells (ECs) 
which form the inner lining of the vessels wall and smooth muscle cells.
Pericytes differentiate from mesenchymal precursors and are recruited to tumors by PDGFβ. 
They possess characteristic cellular markers including 3G5 ganglioside and chondroitin sul-
fate proteoglycan 4 (CSPG4) also known as NG2. In tumor tissue, pericytes highly express 
αSMA, although it is often absent in quiescent pericytes in non-tumoral tissue. Recent experi-
mental studies revealed that pericytes can actively modulate the magnitude of immune 
responses and may prevent lymphocyte extravasation and activation in tumor tissue [9].
ECs are subdivided into tip cells and stalk cells and function as active stromal regulators 
implicated in proliferation, invasion, secretion of inflammatory and growth mediators, and 
metastatic spread. Tip cell is highly migratory and polarized EC type that extends numerous 
filopodia and expresses low level of VEGF receptor 1 (VEGFR1low), with high levels of VEGFR2 
and Delta-like ligand 4 (Dll4), and in vitro CD34. The tip cell is followed by stalk cell, a pro-
liferative and less migratory type of EC, which expresses VEGFR1high, VEGFR2low, Dll4low and 
has undetectable levels of CD34 in vitro [10]. Importantly, neovascular tips are rich in active 
TGF-β1 and periostin, which promote tumor growth and regulate tumor dormancy [11].
2.1.4. Neural and neuroendocrine cells
Cancer cells can support the neoneurogenesis by secreting several neuronal growth factors 
and axon guidance molecules. The majority of factors known to induce neurogenesis, such 
as neurotrophins, insulin-like growth factor-II (IGF-II), and fibroblast growth factor (FGF), 
are usually secreted by tumors with bad prognosis. These factors exert autocrine or paracrine 
effects in cancer cells. Norepinephrine, another neurotransmitter, has a significant impact on 
T-cells. It can inhibit the generation of antitumor cytotoxic T-lymphocytes (CTLs) through the 
inhibition of TNF-α synthesis [11]. The neural-epithelial interaction and nerve growth factor 
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(NGF) production by cancer cells favor tumor progression by promoting both the growth of 
cancer cells and neurites [12].
Neuroendocrine (NE) cells are part of the diffuse NE system and exhibit a combination of 
neuronal and endocrine features. NE system strongly influences the function of the immune 
system. It can regulate the migration and cytotoxicity in natural killer (NK) cells through 
neurotransmitters. Additionally, the neuroendocrine substance P (SP) blocks the β1-integrin-
mediated adhesion of T lymphocytes and increases their migratory activity [13]. SP can also 
induce the production of various cytokines in leukocytes. SP and the subsequent activation of 
the neurokinin-1 receptor (NK1R) lead to mitogen-activated protein kinase (MAPK) activa-
tion. The involvement of NK1R activation in mitogenesis, angiogenesis, cell migration, and 
metastasis supports the hypothesis that SP and NK1R interactions influence the TME [14].
2.1.5. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are multipotent stem cells with the capacity to differentiate 
into fibroblasts, adipocytes, pericytes, osteocytes, and chondrocytes. MSCs express cell sur-
face markers CD29, CD44, CD73, CD90, CD105, and STRO-1, and lack the expression of CD14, 
CD34, CD45, and human leukocyte antigen HLA-DR [15]. MSCs have immunomodulatory 
features and secrete cytokines, VEGF, and immune receptors which regulate the microenvi-
ronment in the host tissue. Based on their multilineage potentiate, immunoregulatory and 
tissue-protective properties, MSCs are being tested for the treatment and prevention of graft-
versus-host disease, chronic diseases, and certain hematologic malignancies [16].
2.2. Extracellular matrix
ECM is composed of proteins (collagens, laminins, and fibronectins), proteoglycans, and hyal-
uronans in a specific organization [17, 18]. CAFs are the major cell type responsible for the 
synthesis of ECM proteins. ECM contains all the cytokines, GFs, and hormones secreted by 
stromal and cancer cells. During tumor progression, ECM composition and structure change 
continuously. ECM heterogeneity is crucial for controlling collective cell-invasive behav-
iors and determining metastasis efficiency. ECM selects survival cancer cells to aid in tumor 
growth and invasion at the fastest rate. ECM can also affect tumor development and metastasis 
through extracellular secretion, or by altering the phenotype of stromal cells or cancer cells [3]. 
Moreover, ECM provides a hypoxic or acidic microenvironment in which cancer cells have 
greater survival advantages. The abundant ECM within the TME is correlated with increased 
tumor growth through various mechanisms, including activation of pro-survival phos-
phoinositide 3-kinase (PI3K)-signaling pathways and downstream of integrin receptors [2].
ECM interacts with lymphocytes and crucially influences immune cells motility and local-
ization, which can help tumor cells to evade from immune surveillance. Increased stroma 
density reduces lymphocyte displacement, supporting the idea that ECM deposition can alter 
antitumor immune responses by limiting T-cell motility [4].
2.3. Immune and inflammatory cells
Tumor microenvironment contains numerous immune and inflammatory cells that originate 
from lymphoid precursors [CD8+ cytotoxic T-cells (CTLs), CD45+ memory T-cells, CD4+ T 
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helper cells (Th1, Th2 and Th17), T regulatory cells (Tregs), T follicular helper cells (TFH), 
NKT cells, gamma delta T (γδ T) cells, B-cells, and plasmacytoid dendritic cells (pDCs)] and 
from myeloid precursors [tumor-associated macrophages (TAMs), myeloid-derived suppres-
sor cells (MDSCs), conventional DCs (cDCs), neutrophils, mast cells, and platelets]. The term 
tumor-infiltrating lymphocytes (TILs) are referred to a group of T-cells (CD3, CD4, CD8, and 
FoxP3) located around tumor cells [19]. In addition, the invasive margins of cancers may 
comprise tertiary lymphoid structures (TLSs) that exhibit strong similarities with lymph node 
organization.
These immune and inflammatory cells infiltrate TME via a network of inflammatory chemo-
tactic cytokines and chemokines produced by cancer cells.
NK cells (CD56+/CD3−) belong to the innate immune system and play an important role in pro-
tecting the host from infections and cancer. NKT cells (CD56+/CD3+) share a variety of markers 
for both T lymphocytes and NK cells. The γδ T-cells are an independent population of circu-
lating lymphocytes that can sense pathogens. γδ T-cells can also induce DC maturation, func-
tional activation and migration, and antigen presentation. NK, NKT cells, and γδ T-cells are 
present in TME in various cancer, and express the natural killer group 2D (NKG2D) receptor. 
NKG2D recognizes proteins encoded by the MICA and MICB locus, which are located within 
the major histocompatibility complex (MHC) on chromosome 6 near the HLAB locus [20].
CD4+ and CD8+ are the two main lineages of T-cells. CD4+ T-cells are classified into CD4+ Th 
that mediate tumor immunity and CD4+ CD25+ FoxP3+ Tregs that suppress antitumor immu-
nity and promote tumor growth [21, 22].
DCs are derived from myeloid precursors (cDCs) or lymphoid precursors (pDCs) and are 
considered as a crucial link between innate and adaptive immunity. DCs have three matura-
tion stages: precursor DCs, immature DCs, and mature DCs. Immature DCs interact with 
antigens, migrate into secondary lymphoid organs, and become antigen-presenting cells 
(APCs). DCs are among the first cells migrating to the tumor site by means of GFs (VEGF and 
HGF), chemokines (CXCL12 and CXCL8), and antimicrobial peptide (β-defensin) secreted by 
cancer cells and stromal cells [23–25].
MDSCs have two distinct monocytic and granulocytic subsets and can differentiate into DCs 
or ECs. They coordinate tumor progression and angiogenesis through the release of MMP-9 
and VEGF. MDSCs can also promote immune evasion by suppressing antitumor CTLs and 
NK cells [26].
TAMs are multifunctional cells characterized by the expression of CD68, plasticity, and secre-
tion of numerous immune-modulatory cytokines. Macrophages differentiation and growth 
are regulated by several GFs, including CSF-1 and GMCSF. TAMs can release chemokines 
(CCL17, CCL18, and CCL22) and recruit non-CTLs, especially Tregs. Activated macrophages 
can be classified into M1 and M2 cells [27]. M1 cells are characterized by high capacity to 
present antigen and are involved in the response of Th1 cells to pathogens and cancer. M1 
cells produce proinflammatory cytokines (TNFα and IFN-γ) and interleukins (IL-1 and IL-12) 
and generate reactive oxygen species (ROS) and nitric oxide (NO). By contrast, M2 cells have 
immunosuppressive phenotype, produce IL-10, and inhibit CTLs, which are crucial to initi-
ate a Th2-type response. Within the TME, TAMs have generally a M2-skewed phenotype 
(CD163+, CD204+, and CD206+) that promote angiogenesis, ECM remodeling, and repair [28].
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During tumor development, pre-invasive TME has antitumor property that includes predom-
inantly M1 and Th1 with the production of IL-12, IFNγ, and inducible NO synthase (iNOS). 
Comparatively, the transition to invasive TME is marked by pro-tumoral properties with a 
shift from M1 to M2 and from Th1 to Th2 cells, a decrease of IFNγ, and an increase of IL-1, 
IL-6, VEGF, and indoleamine 2, 3-dioxygenase (IDO) [29].
Topographically, each type of immune and inflammatory cells has a preferred location within 
tumor site. CTLs and Th1 cells are located at the invasive margins and/or in the tumor core. 
Immature DCs are found in the tumor core, whereas mature DCs infiltrate T-cell zones in 
close contact with CD4+ and CD8+ T-cells. B-cells are found in TLS and at the invasive margins. 
TAMs and TFH are in contact or within B-cell zones, whereas NK cells are dispersed within 
the stroma and at the invasive margins [30].
Tumor-associated TLSs exhibit strong similarities with lymph node organization and com-
prise prominent B-cell follicles, T-cell marginal zones, and associated follicular DCs, very 
few Tregs, and high endothelial venules (HEVs). TLSs are usually located in the tumor-
invasive margin and in the stroma of most cancers and their densities correlate with a favor-
able clinical outcome. HEVs express peripheral node addressins (PNAds) and specialized 
in the extravasation of circulating immune cells, and the secretion of chemokines that are 
crucial for lymphocyte recruitment and entry into the lymph node. Recently, a molecu-
lar signature of TLSs encoding 12 distinct chemokines (CCL2, CCL3, CCL4, CCL5, CCL8, 
CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, and CXCL13) has been identified in 
various tumors [31].
TLSs are associated with the generation of an adaptive immune response and represent a for-
midable school for T-cell priming, B-cell activation, and differentiation into plasma cells and 
an exquisitely located factory for antibody production [32].
3. Host immune response to cancer
3.1. Cancer immune cycle
In the early stage of carcinogenesis, cancer cells are rejected by an innate immune mechanism 
also referred to as immunosurveillance. The innate immune system recognizes exogenous 
pathogen-associated molecular patterns (PAMPs) or endogenous danger-associated molecu-
lar patterns (DAMPs). These latter ones are recognized by the host organism through various 
pattern recognition receptors (PRRs) that activate DNA sensors and downstream adaptors 
to trigger stimulation of innate immune system and to induce adaptive T-cell responses. 
Multiple families of PRRs, including Toll-like receptors (TLRs), have been identified within 
plasma membrane, intracellular vesicles, and within the cytosol of APCs [33]. Binding of 
ligands to PRRs activates various adaptor molecules and downstream signaling pathways, 
orchestrating innate immune responses and maturation of APCs (DCs), leading to production 
of antimicrobial peptides, cytokines, chemokines, and type I interferon (IFN) including IFN-α 
and IFN-β. In cancer, PRRs can also recognize various endogenous DAMPs, such as cancer-
associated antigens (CAAs). Among regulators of innate immune system, recent evidence has 
Histopathology - An Update18
indicated that the major pathway involved in the induction of a spontaneous antitumor adap-
tive T-cell response is the stimulator of interferon genes (STING) signaling [34].
Experimental studies indicate that immune system plays a dual role in cancer, a theory known 
as cancer immunoediting. It can not only eliminate cancer cells or inhibit their growth but 
also promote tumor progression by modifying conditions within TME or by selecting more 
resistant cancer cells. Cancer immunoediting contains three phases: elimination, equilibrium, 
and escape. The immune system is directed against cancer cells through the “cancer immu-
nity cycle” described by Chen and Mellman [35], which associates cancer antigen release by 
tumor cells, presentation by DCs and priming of T lymphocytes in lymph nodes, activation of 
peripheral immune cells, trafficking and infiltration of T-cells to the TME, cancer cells recogni-
tion, and immune-mediated cell death (T-cell-inflamed phenotype). In the elimination phase, 
T-cells attack tumor cells that express tumor-specific antigens in the form of complexes of 
tumor-derived peptides bound to MHC molecules on the cell. Naïve T-cells that differentiate 
in bone marrow express a unique T-cell receptor (TCR) and undergo positive and negative 
selection processes in thymus. T-cells become activated when tumor antigens are recognized. 
Then, T-cells proliferate and differentiate, leading to the T-cell’s ability to attack and destroy 
cells that express relevant antigens. The recognition of antigen-MHC complexes by the T-cell 
antigen receptor is not sufficient for the activation of naïve T-cells. However, the engagement 
of CD28 on T-cell surface and the expression of B7 molecules (CD80 and CD86) on APCs (DCs) 
provide additional costimulatory signals [36]. Cancer cells usually do not express B7 molecules 
(except for certain lymphomas) and hence are largely invisible to the immune system. This can 
be overcome by an inflammatory response, which permits APCs to take up antigen and pres-
ent antigen-MHC along with B7 molecules initially in tumor-draining lymph nodes for effec-
tive activation of T-cells. After the costimulation process, tumor-specific T-cells acquire effector 
function, move to the tumor site, and infiltrate TME, which activates the antitumor immune 
response. However, the antitumor efficacy of T-cells within TME is determined by their abil-
ity to overcome barriers and counter-defenses they encounter from tumor and stromal cells, 
Tregs, MDSCs, and inhibitory cytokines that act to mitigate antitumor immune responses [37].
Activated T-cells express immune checkpoints such as cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4 also known as CD152) and programmed death 1 (PD-1 also known as 
CD279) which act to abrogate T-cells responses. CTLA-4 competes with CD28 for binding to 
CD80/86, providing an inhibitory stimulus upon engagement [38].
PD-1 is a T-cell surface receptor that delivers inhibitory signals upon engagement with its 
ligands. PD-1 ligands (PD-L1 and PD-L2) are expressed via oncogenic expression on tumor 
cells or by stromal cells and may also be upregulated in the setting of high levels of IFN-γ, 
termed adaptive immune resistance [39].
During tumor development, a subpopulation of non-immunogenic cancer cells develops 
new mechanisms to evade immune surveillance and induce tumor tolerance. They include 
decreased expression of MHC-I and expression of immunosuppressive factors that contrib-
ute to escape from immune recognition. Consequently, tumors display a strong immune-
suppressive TME and fail to elicit an appropriate adaptive immune response. This TME is 
associated with several molecular mechanisms in place to interfere with CTLs, resulting in 
poor infiltration of reactive tumor-rejecting T-cells [40].
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After an efficient immune response, immune tolerance reduces ability for immune-mediated 
tumor eradication by associating upregulation of tumor and immune cells PD-L1, DCs and 
macrophages IDO expression in response to IFNγ signaling, expression of additional immuno-
suppressive checkpoints (LAG3), and enhanced regulatory T-cells and MDSCs activities [41].
An innate immune response leads to activation of the adaptive immune system (B- and T-cells), 
provided direct interactions with APCs and a proinflammatory environment. Primary adap-
tive responses are slower than the innate responses, as clonal expansion due to the recogni-
tion of foreign antigens is required.
The current understanding of the dichotomous nature of immune cells in tumors is that IFN-
γ-producing CD4+ Th1 and CD8+ CTL along with mature DCs, NK cells, M1 macrophages 
and type 1 NKT cells can generate antitumor responses. Conversely, CD4+ Th2, CD4+ Tregs, 
MDSCs, immature DCs, M2 macrophages, and type 2 NKT cells promote tumor tolerance 
and support tumor growth and progression [40]. Furthermore, the knowledge on the crucial 
antitumor activity of the immune system has generated great interest in immunotherapy of 
cancer, including non-immunogenic tumors.
3.2. Humoral immune response in cancer
The production of autoantibodies (AAbs) reflects the immunologic reactivity in cancer 
patients and enhances immune surveillance for cancer cells. AAbs level is detectable in very 
early cancer stages and may persist for an extended period after cancer removal, reflecting 
the overall host immune response toward the tumor. It is interesting to note that a repertoire 
of AAbs is shared by autoimmune diseases and cancer, suggesting that autoimmune con-
ditions share many parallels with the humoral immune response to tumor-associated anti-
gens (TAAs) [42]. Tolerance defects, inflammation, posttranslational modifications, and cell 
death can affect TAA immune presentation, contributing to cancer-related AAbs production. 
Recently, AAbs have become useful diagnostic, prognostic, and surveillance cancer biomark-
ers as they can be easily detected in the serum of cancer patient [43].
3.3. Genetic and germline polymorphisms of immune system
Genetic polymorphism is an alternative phenotype that appears to be widespread among the 
genes of the immune system and can correspond to an evolutionary adaptation of the host 
organism facing an environment in constant evolution. Several polymorphisms concerning 
genes that encode Janus kinase/signal transducer and activator of transcription (JAK/STAT), 
TLR genes, TNF-α, NF-κB, NOD2, autophagy-related protein 16 (ATG16), and receptors for 
the Fc domain of immunoglobulins (FcR), are involved in the immune responses in cancer 
development or affect the potency of certain anticancer therapies.
JAK/STAT-signaling pathway plays a key role in the regulation of cellular responses to cyto-
kines (IFN-α, IFN-β, IFN-γ, and IL). It has been demonstrated that genetic polymorphism 
involved in JAK/STAT (STAT3 and STAT4) pathway is associated with the risk of non-Hodg-
kin lymphoma [44]. Moreover, polymorphisms in TLR genes may shift balance between pro- 
and anti-inflammatory cytokines in the host, contributing to the onset and progression of 
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cancers. Recent evidence has implicated polymorphisms of FcRs in the efficacy of monoclonal 
antibody (mAb)-mediated therapy. Interestingly, the therapeutic effects of IgG1 mAbs (ritux-
imab and trastuzumab) are partially mediated by the FcγR immune response, suggesting that 
polymorphisms of FcγRs may affect the potency of the mAb treatment [45].
3.4. Microbiota
The microbiota is composed of commensal bacteria and other microorganisms that live on 
the epithelial barriers of the host. Microbiota influences physiological functions including the 
maintenance of barrier homeostasis and the regulation of metabolism, hematopoiesis, inflam-
mation, and immunity. Recent data demonstrated the involvement of microbiota in cancer ini-
tiation, progression, and dissemination. In addition, gut microbiota can modulate the response 
to chemotherapy, radiotherapy and immunotherapy, and susceptibility to toxic side effects. 
Therefore, targeting the microbiota may improve anticancer efficacy and prevent toxicity [46].
3.5. Environmental factors
Immunity in humans can also be affected by environmental factors, including the presence 
of infectious agents, diet, exposure to sunlight (photoimmunity), and the intake of pharma-
ceuticals. Interestingly, during periods of decreased exposure to sunlight the human immune 
responses are associated with enhanced levels of IL-6 and C-reactive protein, which are linked 
to an increased propensity for autoimmunity. Therefore, it is acceptable to believe that low 
sunlight conditions may correlate with a more inflammatory systemic environment, leading 
to better responses to cancer immunotherapy [47].
4. Tumor microenvironment and immune scoring
4.1. Glasgow microenvironment score
Glasgow microenvironment score (GMS) is a cumulative prognostic score that combines 
Klintrup-Mäkinen (K-M) grade and tumor stroma percentage (TSP) and has an independent 
prognostic value. K-M grade semiquantitatively evaluates the peritumoral immune cell type 
and density at the invasive margin of the deepest point of tumor invasion using H&E-stained 
FFPE tissues. K-M grade is classified into (1) low-grade K-M: no increase or mild increase in 
inflammatory cells, and (2) high-grade K-M: prominent inflammatory reaction that forms a 
band at the invasive margin, or florid cup-like infiltrate at the invasive edge with destruction 
of cancer cell islands [48, 49]. K-M grade could be assessed by IHC-stained sections using 
CD3, CD8, CD45R0, and FoxP3 antibodies to evaluate immune T-cell type [49]. TSP evaluates 
the percentage of stroma using complete sections of the deepest point of tumor invasion. The 
proportion of stroma is calculated as the visible field at 10× objective, excluding areas of mucin 
and/or necrosis [50]. TPS is subsequently graded as low TSP (≤50%) or high TSP (>50%) [49]. 
The global GMS score is subdivided into three GMS categories: (GMS 0: high-grade K-M), 
(GMS 1: low-grade K-M/low-grade TSP), and (GMS 2: low-grade K-M/high-grade TSP) [51].
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4.2. Microenvironment cell populations-counter
Microenvironment cell populations (MCP)-counter is a transcriptome-based computational 
method that quantifies the abundance of 10 stromal and immune cell populations in TME 
using a single-gene expression experiment. MCP-counter produces an abundance score for 
CD3+ T-cells (CD3D and CD5), CD8+ (CD8B) and CTLs (EOMES and GNLY), B lymphocytes 
(CD19, CD79A, and CD79B), NK cells (NKp46 and KIR genes), monocytic lineage (CSF1R), 
myeloid DCs (CD1), neutrophils (FCGR3B and CD66b), as well as fibroblasts (DCN and 
TAGLN) and ECs (CDH5). These scores can then be used for direct comparisons of the abun-
dance of the corresponding cell type across samples within a cohort. MCP-counter was quan-
titatively validated by both using mRNA mixtures and IHC in FFPE tissues. This method 
can reproduce immunological and stromal prognostic classifications associated with overall 
survival in lung adenocarcinoma and colorectal and breast cancers [52]. However, the loss 
of spatial cell’s localization is one of limitations when using such transcriptomic technology. 
Thus, histological confirmation of MCP-counter seems to be necessary in cases where con-
tamination of samples by surrounding non-tumoral tissues is unavoidable.
4.3. Cancer transcriptomic signature
A transcriptomic classification of colorectal cancer has been recently proposed that stratifies 
colorectal cancer into intrinsic subtypes with different prognosis. This classification is subdivided 
into four consensus molecular subtypes (CMS): CMS1 (MSI-like subtype) that contains most mic-
rosatellite instability (MSI) tumors and BRAF mutations, CMS2 (canonical subtype) with high 
chromosomal instability (CIN), CMS3 (metabolic subtype) includes tumors with KRAS muta-
tions and shows a disruption of metabolic pathways, and CMS4 (mesenchymal subtype) that 
concerns tumors with frequent CpG-island methylator phenotype (CIMP) [53]. Interestingly, 
a recent comparative study has demonstrated three microenvironmental signatures that corre-
spond to each molecular subtype. The CMS1 was associated with the overexpression of genes 
specific to cytotoxic lymphocytes, and a good prognosis. Conversely, CMS4 revealed proinflam-
matory, proangiogenic, and immunosuppressive signature and was associated with poor prog-
nosis. Finally, CMS2 and CMS3 showed almost similar TME profile and were associated with 
low immune and inflammatory signatures, and intermediate prognosis [54] (Table 2).
Comparatively, in triple-negative breast cancer, three TME subtypes using IHC analyses have 
been identified: (1) a first subtype with TLR9high expression by cancer cells, hypercellular stroma 
and numerous TILs overexpressing TLR9; (2) a second subtype with TLR9low expression by 
cancer cells, a predominantly paucicellular stroma, and rare inflammatory cells expressing 
TLR9 without TILs; and (3) a third subtype with TLR9low expression by cancer cells, a predomi-
nantly fibrotic and vascular stroma containing some immune and inflammatory cells [55].
4.4. Tumor microenvironment of metastasis score
Tumor microenvironment of metastasis (TMEM) score is an IHC-staining score assessed by 
three antibodies: anti-CD31, anti-CD68, and anti-panMena. The selected area should be identi-
fied by low power, focusing on representative high density and adequacy of tumor, and lack 
of necrosis, inflammation, and artifacts. TMEM is defined as a structure composed of the direct 
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contact between an invasive pan Mena-overexpressing carcinoma cell, an endothelial cell 
(CD31+), and a perivascular macrophage (CD68+), with no discernible stroma between tumor 
cell and perivascular macrophage. Then, the number of TMEMs per 10 high-power fields 
(×400) is calculated to give a final TMEM score for each patient sample [56, 57]. In breast cancer, 
TMEM score is positively associated with risk of distant metastasis in ER+/HER2− patients [57].
4.5. Recommendations for assessing TILs in breast cancer
A group of experts has proposed a step-by-step recommendation of how TILs should be 
evaluated by pathologists in breast carcinoma tissue samples [58], whether it can be on core 
biopsies or full surgical sections:
• One section (4–5 μm, magnification × 200–400) per patient is considered to be sufficient.
• Full sections are preferred over biopsies whenever possible.
• TILs should be evaluated within the borders of the invasive tumor.
Consensus molecular 
subtypes (CMS)
Molecular characteristics 
[53]
MCP-counter signature 
[54]
Mechanisms of 
action
Prognosis
CMS1 MSI-like 
subtype
• MSI tumors with muta-
tions in genes encoding 
DNA mismatch-repair 
proteins, resulting in 
high mutational burden
• Tumors with a CIMP 
and BRAF mutations
Overexpression of genes 
specific to cytotoxic 
lymphocytes
High expression 
of genes coding 
for T-attracting 
chemokines 
(CXCL9, CXCL10, 
and CXCL16) or 
TLS’s formation 
(CXCL13), Th1 
cytokines IFNG and 
IL15
Good 
prognosis
CMS2 Canonical 
subtype
• Tumors with high chro-
mosomal instability
• Activation of the Wnt 
and MYC pathways
Low immune and 
inflammatory signatures
Intermediate 
prognosis
CMS3 Metabolic 
subtype
• Tumors with KRAS 
mutations and disrup-
tion of metabolic 
pathways
Low immune and 
inflammatory signatures
Intermediate 
prognosis
CMS4 Mesenchymal 
subtype
• Tumors with mesen-
chymal phenotype 
and frequent CIMP 
phenotype
Expression markers 
of lymphocytes and 
of cells of monocytic 
origin. Proinflammatory, 
proangiogenic, and 
immunosuppressive 
signature
High expression of 
myeloid chemokine 
CCL2, complement 
components, 
angiogenic factors 
(VEGFB, VEGFC, 
and PDGFC), and 
immunosuppressive 
molecules (TGFB1, 
TGFB3, LGALS1, 
and CXCL12)
Poor 
prognosis
Table 2. Cancer transcriptomic signature: molecular subtypes versus tumor microenvironment signature.
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• TILs should be reported as percentage for the stromal compartment (percentage of stromal 
TILs).
• TILs should be assessed as a continuous parameter. The percentage of stromal TILs is a 
semiquantitative parameter for this assessment, for example, 80% stromal TILs means that 
80% of the stromal area shows a dense mononuclear infiltrate.
• All mononuclear cells (including lymphocytes and plasma cells) should be scored, but 
polymorphonuclear leukocytes are excluded.
• Do not focus on hotspots: a full assessment of average TILs in the tumor area should be used.
• Exclude TILs outside of the tumor border and around DCIS and normal lobules.
• Exclude TILs in tumor zones with crush artifacts, necrosis, regressive hyalinization as well 
as in the previous core biopsy site.
4.6. PDL-1/TILs score
Tumors can be classified into four groups based on their PD-L1 expression and the presence 
or absence of TILs [59, 60] (Table 3). The type of tumors that fit into each of PD-L1/TILs status 
depends on the genetic aberrations and oncogene drivers of these tumors. In melanoma, a 
high proportion of type I (~38%) and type II (~41%) tumors is observed, with the former hav-
ing considerably the best prognosis [59]. Comparatively, pancreatic cancer has a lower level of 
PD-L1 expressed on tumor and immune cells [61]. By contrast, in non-small-cell lung cancer 
(NSCLC) where the oncogenes are more important drivers of tumor PD-L1 expression, the 
frequency of type III may be higher. In NSCLC, PD-L1 positivity is associated to adenocarci-
noma and the presence of EGFR mutations, whereas PD-1 is associated with smoking status 
and the presence of KRAS mutations [62]. Additionally, increased levels of CD3 and CD8+ are 
associated with better outcome in NSCLC [63].
Accumulating data suggest that two major categories of immune resistance within the TME 
may exist: (i) failure of T-cell trafficking due to low levels of inflammation and lack of chemo-
kines for migration, and (ii) dominant suppression through immune-inhibitory mechanisms. 
The potential reasons explaining failed tumor rejection in the cases of T-cell-inflamed TME 
include extrinsic inhibition by PD-L1/PD-1 interactions and the suppression effect of Tregs [64].
Expression 
groups
PDL-L1/TILs status Significations
Group I PD-L1+, with presence of TILs Drives adaptive immune resistance
Group II PD-L1−, with no TIL Indicates immune ignorance
Group III PD-L1+, with no TIL Indicates intrinsic induction
Group IV PD-L1−, with presence of TILs Indicates the role of other suppressor in promoting immune 
tolerance
Table 3. PDL-1/TILs score: tumors can be classified into four groups based on their PD-L1 expression and presence or 
absence of TILs.
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4.7. PD-L1 tumor proportion score
Immunotherapies with checkpoint inhibitor PD-L1, which can inhibit T-cell function 
by binding PD-1 on T-cells, have shown encouraging results in patients with advanced 
NSCLC. Several agents such as pembrolizumab, nivolumab, atezolizumab, and durvalumab 
are approved or under clinical development for patients with metastatic NSCLC. Clinical tri-
als have shown an association between the degree of clinical efficacy of these drugs and the 
level of PD-L1 expression by IHC. In two recent comparative trials, at least three PD-L1 IHC 
antibodies (22C3, 28–8, and SP263) are aligned regarding PD-L1 expression on tumor cells 
[65, 66]. A cancer cell is considered PD-L1 positive only when cell membrane is partially or 
completely stained. By contrast, an immune cell is considered PD-L1 positive if it features any 
PD-L1 staining: cell membrane or cytoplasm. PD-L1-positive immune cells are predominantly 
macrophages and lymphocytes. All assays revealed PD-L1 expression on immune cells, but 
with greater variance than expression on tumor cells. Alveolar macrophages are consistently 
stained with anti-PD-L1 antibody, serving as an internal positive control.
In NSCLC, PD-L1 tumor proportion score (TPS) is proposed to evaluate the IHC expression 
on tumor cells. The cutoffs of the different scoring criteria may be integrated into a six-step 
scoring system (Cologne Score: <1, ≥1, ≥5, ≥10, ≥25, ≥50%).
Currently, pathologists are confronted with two situations to evaluate TSP:
First-line metastatic NSCLC: Pembrolizumab is indicated in first-line setting as both monother-
apy and combination therapy in metastatic NSCLC, which has TPS of ≥50%, with no EGFR or 
ALK genomic aberrations [67].
Second-line metastatic NSCLC: Pembrolizumab is indicated in second-line treatment of meta-
static or locally advanced NSCLC, which has PD-L1 TPS of ≥1%. In this case, patients with 
EGFR or ALK genomic aberrations should have disease progression on therapy for these 
aberrations prior to receiving Pembrolizumab [61].
The above-cited data underline the importance of PD-L1 test as a biomarker in immunother-
apy of NSCLC even in the first-line treatment. Nevertheless, the priority remains to harmonize 
the procedure of PD-1 testing and interpretation, which might require specific standardiza-
tion. Therefore, pathologists have a major role to put in place the PDL-1 IHC test in routine 
practice and determine PDL-1 immunoscore on FFPE tissues.
5. Strategy panels in immunotherapy
Systemic anticancer therapies have evolved from chemotherapy through targeted therapies to 
immune agents and immunotherapy, which is now considered as the third paradigm in cancer 
treatment. Events from cancer immunity cycle and immune tolerance may serve as both pre-
dictive biomarkers and potential therapeutic targets. Immunotherapy is emerging as a novel 
therapeutic strategy promoting immune response against cancer cells and differing from tra-
ditional modalities that target tumor cells directly. Preclinical and clinical evidence provides 
the rationale for different promising immunotherapeutic approaches combining upregulation 
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of immune responses and downregulation of immune tolerance, to edify a cancer immunity 
cycle or to re-activate a neutralized preexisting anticancer immune response [68].
Immunotherapies are most effective in patients with a T-cell-inflamed phenotype. Initially, 
immunotherapy using high-dose interleukin 2 and adoptive T-cell transfer allowed durable 
clinical benefit in patients with advanced malignancies. Currently, immune strategies have 
shifted to targeted manipulation of immune checkpoints. Immune checkpoints refer to mul-
tiple inhibitory and costimulatory pathways that counteract certain crucial steps of T-cell-
mediated immunity to maintain self-tolerance and modulate the duration and amplitude of 
immune responses. Immune checkpoints are initiated primarily through T-cell inhibiting and 
stimulating receptors and their ligands, including CTLA-4 (CD152), PD-1 (CD279) and PD-L1 
(CD274) or PD-L2 (CD273), among many others [41]. The CTLA-4 antibody ipilimumab was 
the first approved checkpoint inhibitor after it improved overall survival in patients with 
advanced melanoma in two randomized phase III trials. However, objective responses are 
low with ipilimumab monotherapy and 22% of patients with advanced melanoma survived 
at least 3 years after therapy. Greater clinical benefit has been observed with inhibitors tar-
geting PD-1 or PD-L1 checkpoints. The anti-PD-1 inhibitors pembrolizumab and nivolumab 
have been recently approved by the US Food and Drug Administration (FDA) for patients 
with advanced unresectable melanoma, NSCLC, and metastatic renal-cell carcinoma, with 
objective responses in 40–45, 20, and 25% of patients, respectively. FDA approvals have been 
announced for nivolumab in patients with refractory Hodgkin’s lymphoma and for the anti-
PD-L1 agent atezolizumab in patients with advanced bladder cancer. Furthermore, signifi-
cant clinical benefit, including durable tumor responses and extension of progression-free 
and overall survival, has now been observed with other anti-PD-1 and anti-PD-L1 inhibitors 
in a wide spectrum of solid tumors and hematological malignancies [69, 70].
However, significant responses to immunotherapy only occur in a minority of patients. Attempts 
are being made to improve the activity of immunotherapies with novel combinatorial strategies 
and with biomarker optimization. Immuno-oncology drugs are thus currently evaluated and 
data from recent clinical phase I–III trials have highlighted the potential for combination thera-
pies, including these immunomodulating inhibitory molecules (TIM-3, VISTA, LAG-3, IDO, 
and KIR) and costimulatory antibodies (CD40, GITR, OX40, CD137, ICOS) [41, 71, 72].
6. Biomarkers in immuno-oncology
Selection of patients based on validated predictive biomarkers is an important issue that needs 
to be addressed. Although most of immunotherapies are dedicated to T lymphocytes and 
cell-mediated cytotoxicity, cancer immune response is a very complex process characterized 
by numerous reciprocal interactions between tumor cells, multiple immune/stromal cellular 
subtypes, soluble mediators, ECM, and blood vessels. A wide spectrum of biomarkers is thus 
required to guide anticancer immune strategies. Immunotherapeutic agents function through 
different mechanisms of action, including modulation of T-cell receptors (CTLA-4 and PD-1) 
and adoptive T-cell therapies that associate TILs, chimeric antigen receptors (CARs), and 
TCR-modified T-cells. Furthermore, tumor spatio-temporal heterogeneity is characterized by 
different antigenic profiles over time (before and after treatment) and topography ( primitive 
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and metastatic tumor) and numerous immunosuppressive mechanisms are promoted in the 
TME. Most importantly, discovering and optimizing immuno-oncology biomarkers could 
predict sensitivity or resistance to these immunomodulating molecules, identify their mecha-
nisms of action, and define efficient combined therapies to rationally select patients. Thus, 
characterizing the anticancer immune response with multidisciplinary and multiparametric 
NGS and in situ technologies is pivotal to identify multiplex profiles that could allow patient’s 
stratification for optimal personalized immunotherapy [73].
According to the thematic hallmarks of anticancer immune response, a large spectrum of 
potential biomarkers that could predict response to immunotherapy have been recently iden-
tified, including (i) tumor foreignness: tumor immunogenicity, high mutational load, gene 
expression profiling, epigenetic modifications of immune genes, intra-tumor heterogeneity; 
(ii) immunosuppressive tumor metabolism: LDH and TGFβ levels; (iii) host immune status: 
total lymphocyte count, T-cell and B-cell repertoire, antitumor antibodies titers, preexisting 
autoimmunity; (iv) immune regulation: antigen presentation (CD40/CD40L), cancer cells 
reduced MHC expression, T-cell recognition, TCR repertoire diversity, IFNα and TNFα levels; 
(v) immune cells migration: T-cell trafficking chemokines (CCL5, CXCL9, and CXCL10), che-
mokines profile, VEGF levels, inflammatory signature; (vi) tumor immune infiltration: CD8+ 
TILs, FoxP3+ Tregs; (vii) T-cell cytotoxicity: granzyme A, perforin 1, and IFNγ levels; and (viii) 
immunosuppressive molecules: CTLA4, PDL1, PDL2, LAG3, TIM3, and IDO [73, 74].
These multiple predictive biomarkers present potential great interest in future practice to 
select patients for optimal immunotherapy: (i) PD-L1 expression in the TME may indicate 
increased sensibility to PD-1/PD-L1 checkpoint inhibitors; (ii) the presence of TILs suggests a 
preexisting antitumor immune response that can be reinitialized by immunotherapy; (iii) high 
tumor mutational load and neoantigens may be indicative of high tumor immunogenicity and 
sensitivity to immunotherapy; and (iv) the presence of immunosuppressive cells (immature 
DCs, MDSCs, TAMs, and Tregs), polarization of macrophages (anti-inflammatory M2 mac-
rophages) and DCs (immunosuppressive/tolerogenic regulatory DCs), immunosuppressive 
molecules and immunoinhibitory cytokines may predict resistance to immunotherapy [72, 75].
Currently, only PD-L1 IHC assays have been validated for clinical utility, although several 
tumors, host, and environmental biomarkers are very promising candidate for patients’ 
stratification. NGS and in situ technologies investigating tumor-immune interactions include 
multiplex immunohistochemistry (multiplexed-IHC), whole-exome sequencing (WES), 
transcriptome analysis, proteomics, and flow cytometry. However, before clinical applica-
tion, each of these potential biomarkers requires high-quality validation process, comprising 
assessment of basic assay performance, characterization of the performance of the assay, and 
validation in clinical trials.
Recent technological advances have provided new tools that will facilitate an in-depth under-
standing of the interaction between the immune system and tumor cells, particularly in the TME 
and will help guide the development of personalized cancer immunotherapies. Data generated 
from these innovative technologies (i.e., gene microarray, deep-sequencing technologies, mass 
cytometry, and multicolor IHC staining) are classified into three categories: (i) function (to eval-
uate the function of different immune cells), (ii) phenotype (to provide the frequency and status 
of these cells), and (iii) signature/pattern (to elucidate the potential mechanisms of action) [76].
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Among these novel technologies, multiplex immunohistochemistry (multiplexed-IHC) 
appears as very effective and efficient method to identify on the same section and at the same 
time, several immune cell types, their location, and their state of activation, as well as the 
presence of immunoactive molecular expression. Multiplexed-IHC is a quantitative, image 
analysis-based method, using multicolor IHC on FFPE tissues, automated multispectral slide 
imaging, and advanced recognition software. When coupled with fluorophores (fluorescence 
multiplexed-IHC), this method takes advantage of light emission with different spectral 
peaks against a dark background (Figures 2A, B and 3). Fluorescence multiplexed IHC pro-
vides spatial localization and distribution of phenotypic and functional biomarkers within 
the TME and thus is highly beneficial in experimental research for exploring immune evasion 
mechanisms or finding potential biomarkers [77].
7. Conclusion and perspectives
After chemotherapy and targeted therapy, immunotherapy has become the third paradigm 
in cancer. Immunotherapy is a key component of the therapeutic strategies to control and 
Figure 2. Fluorescent multiplex immunohistochemistry. (A) Breast cancer, section from tumor’s core, and (B) section 
from invasive margin of the same tumor. The sections are stained with cytokeratin (cancer cells, in green), CD45RO 
(memory lymphocytes, in red), CD4 (T helper cells, in orange) and FoxP3 (in blue).
Figure 3. Fluorescent multiplex immunohistochemistry. Tertiary lymphoid structure panel stained with CD20 (B cells, in 
green), CD3 (CD3+ T lymphocytes, in purple), DC-Lamp (mature DCs, in blue), CD21 (follicular DCs) and PNAd (high 
endothelial venule, in yellow).
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potentially cure cancer. The complexity and heterogeneity of the interaction between the 
immune system and tumor cells, particularly in the tumor microenvironment, underlies the 
immune status (i.e., immunologically responsive or immunologically ignorant) of each tumor 
for every patient. These reciprocal interactions depend on the organ, the oncogenic processes, 
and their modification by treatments. Although immunomodulation by checkpoint inhibi-
tors (targeting both CTLA-4 and the PD-1/PD-L1 axis) induced a durable tumor response in 
several malignancies, the use of PD-L1 immunohistochemistry alone has not been sufficient 
for ruling in or out the use of anti-PD-1 or anti-PD-L1 expression-based therapies. Therefore, 
characterization of recognized tumor antigens, effector T-cell function, and immune-sup-
pressive mechanisms, TILs, T-cell receptor repertoire, and mutational or neoantigen burden 
should be aimed at creating an optimized model for predicting response to anti-PD-1 or anti-
PD-L1 therapies. Furthermore, specific mechanisms of T-cell exclusion such as activation of 
the WNT/β-catenin-signaling pathway, microbiota status, and genetic polymorphism should 
be included in future biomarker development (Table 4).
Accumulating evidences support that the optimal strategy for further immunotherapy devel-
opment is combinatory regimens. The challenge of increasing the curative immune responses 
in a diverse population of patients will require multiple complementary therapeutic modali-
ties to overcome the immunosuppressive tumor microenvironment. Thus, understanding 
the tumor microenvironment may offer opportunities to predict response to therapy and 
select the most appropriate immunotherapy for each patient. The recent availability of high-
throughput next-generation sequencing and in situ technologies to quantify the different ele-
ments of the tumor microenvironment and understand their functionality opens the way for 
generalization of these approaches and the subsequent application of precision-personalized 
therapies based on these landscapes rather than on cancer subtypes only.
Stratification factors Tumor microenvironment subtypes Cancer immune 
set point
Morphology Immune/
inflammatory
Mesenchymal Paucicellular/
inactive
Immunophenotype Immune response Immune exclusion Immune desert
Biological mechanisms Tumor infiltration 
by cytotoxic T-cells, 
B-cells, MDSCs, 
NK cells regulatory 
T-cells, CAFs
Stromal-based 
inhibition from 
vessels, ECM, 
chemokines
Absence of 
preexisting 
antitumor immunity 
(ignorance, tolerance, 
no priming of T-cells)
Biomarkers
Tumor genome/epigenome
Tumor mutation load High Low Low Positive effect
Neoantigen burden High Low Low Positive effect
Gene expression profiling Activation 
signaturehigh
Activation 
signaturelow
Activation 
signaturevery low
Tumor cells PD-L1 High Low Low Negative effect
Tumor infiltration by TILs High Absent Absent Positive effect
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Stratification factors Tumor microenvironment subtypes Cancer immune 
set point
Antigen immunogenicity High Low Low Positive effect
KRAS, BRAF, B2M  MHC  
IDO
High Low Low Negative effect
Hypoxia High Low Low Negative effect
Tumor microenvironment
Immune cells High High Very low/absent
Immune cells phenotypes
Spatial relationship
Effector cellshigh
Immunosuppressive 
cellslow
Effector cellslow
Immunosuppressive 
cellshigh
Very rare myeloid 
and CD8+ cells
Negative/
positive effect
Immune cells PD-L1 High Low Low Positive effect
Immune gene signatures High Low Low Positive effect
Fas-L, TGF-β, LOX, VEGF, 
collagen, fibronectin, CXCL12
Low High Low Negative effect
Host immunity/genetics
T-cell clonal diversity High clonality Low clonality Low clonality Negative/
positive effect
Priming of immune response High Low Low Positive effect
General antibody response Robust Weak Weak Positive effect
Chronic inflammation/
cytokines
Proinflammatory 
cytokines
Immunosuppressive 
cytokines
Immunosuppressive 
cytokines
Negative/
positive effect
Germline polymorphism: 
TLR4, TNF-α, NF-κB, NOD2, 
JAK-STAT, inflammasome 
pathway
Present Absent Absent Negative effect
Environment
Gut microbiota Positive effect
Stress hormones
Glucocorticoids
Negative effect
Immunotherapy Sensitivity Resistance Resistance
Therapeutic strategy Immune checkpoint 
inhibitors
Other 
immunotherapies
Surgery, 
radiotherapy 
chemotherapy, 
vaccination
Adaptive cellular 
therapy
Surgery, 
radiotherapy 
chemotherapy, 
vaccination
Adaptive cellular 
therapy
Table 4. A summary table describes the stratification factors implicated in the interactions between immune 
system, tumor microenvironment, and tumor cells, which can influence immunotherapy and therapeutic strategies 
(immunophenotype, tumor genome/epigenome, tumor microenvironment, Microbiota, environmental factors, host 
immunity and genetics). This table proposes global tumor microenvironment morphological-, immunophenotypical- 
and biological-based subtypes with linked immune biomarkers.
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